{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:28:11Z","timestamp":1771572491043,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005014","name":"Avicenna Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005014","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.biologicals.2020.08.007","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T07:44:37Z","timestamp":1598341477000},"page":"60-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Optimized dose of synthetic analogues of Monophosphoryl lipid A as an effective alternative for formulating recombinant human papillomavirus vaccine"],"prefix":"10.1016","volume":"68","author":[{"given":"Amin","family":"Azimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheida","family":"Heidarian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Homa","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nastaran","family":"Taleghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Dehghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan","family":"Seyedjafari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2020.08.007_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.biologicals.2020.08.007_bib2","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2165\/00003495-200666090-00008","article-title":"Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil\u00ae)","volume":"66","author":"Siddiqui","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.biologicals.2020.08.007_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1517\/14712598.7.3.391","article-title":"Cervarix\u2122 \u2013 a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer","volume":"7","author":"Crosbie","year":"2007","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.biologicals.2020.08.007_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4161\/hv.3.4.4309","article-title":"Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice","volume":"3","author":"Caulfield","year":"2007","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.biologicals.2020.08.007_bib5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/11591760-000000000-00000","article-title":"Development of an AS04-adjuvanted HPV vaccine with the adjuvant system Approach","volume":"25","author":"Gar\u00e7on","year":"2011","journal-title":"BioDrugs"},{"key":"10.1016\/j.biologicals.2020.08.007_bib6","series-title":"Recommendations to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines. Replacement of: TRS 962, Annex 1","year":"2015"},{"key":"10.1016\/j.biologicals.2020.08.007_bib7","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.biologicals.2020.08.007_bib8","series-title":"Vaccine design: the subunit and adjuvant approach","first-page":"495","article-title":"Monopbospboryl lipid A as an adjuvant past experiences and new directions","author":"Ulrich","year":"1995"},{"key":"10.1016\/j.biologicals.2020.08.007_bib9","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00449-016-1648-z","article-title":"Kinetics of infected insect cell osmolysis and enhanced protein release using a modified disruption method","volume":"39","author":"Mirhassani","year":"2016","journal-title":"Bioproc Biosyst Eng"},{"key":"10.1016\/j.biologicals.2020.08.007_bib10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/apm.12927","article-title":"Immunogenicity of HPV and HBV vaccines: adjuvanticity of synthetic analogs of monophosphoryl lipid A combined with aluminum hydroxide","volume":"127","author":"Taleghani","year":"2019","journal-title":"APMIS"},{"key":"10.1016\/j.biologicals.2020.08.007_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bej.2018.12.011","article-title":"Comprehensive study on Wave bioreactor system to scale up the cultivation of and recombinant protein expression in baculovirus-infected insect cells","volume":"143","author":"Ghasemi","year":"2019","journal-title":"Biochem Eng J"},{"key":"10.1016\/j.biologicals.2020.08.007_bib12","unstructured":"European pharmacopoeia 8.0."},{"key":"10.1016\/j.biologicals.2020.08.007_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4161\/hv.4.6.6912","article-title":"Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16\/18 cervical cancer vaccine","volume":"4","author":"Dessy","year":"2008","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.biologicals.2020.08.007_bib14","series-title":"Human papillomavirus laboratory manual","year":"2009"},{"key":"10.1016\/j.biologicals.2020.08.007_bib15","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2020.08.007_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/14760584.6.2.133","article-title":"New hepatitis B vaccine formulated with an improved adjuvant system","volume":"6","author":"Kundi","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.biologicals.2020.08.007_bib17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives","volume":"6","author":"Gar\u00e7on","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.biologicals.2020.08.007_bib18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/156802608783378882","article-title":"Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics","volume":"8","author":"David","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.biologicals.2020.08.007_bib19","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1080\/07328309808002363","article-title":"Chemical synthesis of the major constituents of Salmonella Minnesota monophosphoryl lipid A","volume":"17","author":"Johnson","year":"1998","journal-title":"J Carbohydr Chem"},{"key":"10.1016\/j.biologicals.2020.08.007_bib20","series-title":"Immunopotentiators in modern vaccines","first-page":"161","article-title":"Development and evaluation of AS04, a novel and improved immunological adjuvant system containing MPL and aluminium salt","author":"Gar\u00e7on","year":"2006"},{"key":"10.1016\/j.biologicals.2020.08.007_bib21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.4161\/hv.8485","article-title":"Cervarix\u2122, the GSK HPV-16\/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions","volume":"5","author":"Le Tallec","year":"2009","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.biologicals.2020.08.007_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4161\/hv.6.5.11023","article-title":"Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix\u2122, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine","volume":"6","author":"Deschuyteneer","year":"2010","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.biologicals.2020.08.007_bib23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1099\/0022-1317-77-3-465","article-title":"Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae","volume":"77","author":"Hofmann","year":"1996","journal-title":"J Gen Virol"},{"key":"10.1016\/j.biologicals.2020.08.007_bib24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","article-title":"Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant","volume":"40","author":"Pedersen","year":"2007","journal-title":"J Adolesc Health"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104510562030097X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104510562030097X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T01:14:19Z","timestamp":1760922859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104510562030097X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":24,"alternative-id":["S104510562030097X"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2020.08.007","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimized dose of synthetic analogues of Monophosphoryl lipid A as an effective alternative for formulating recombinant human papillomavirus vaccine","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2020.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}